In this week’s episode of DeviceTalks Weekly, we talk with venture capital investors about how they’re building and maintaining their medtech portfolios during this pandemic landscape.
Our guests this week are…
- Justin Klein, MD, managing partner, Vensana Capital
- Duke Rohlen, chairman, Ajax Health
Together, Klein and Rohlen have created, backed and sold medtech companies that have generated billions.
Klein, formerly of New Enterprise Associates, now co-manages his own venture firm, Vensana Capital. He previously served on the board of directors of Cartiva (acquired), ChromaCode, CV Ingenuity (acquired), EPIX Therapeutics (acquired), FIRE1, GPB Scientific, Intact Vascular, Metavention, Personal Genome Diagnostics, PhaseBio Pharmaceuticals (IPO), Relievant Medsystems, Senseonics (IPO), Topera (acquired), Ulthera (acquired), Vertiflex (acquired), Vesper Medical, and VytronUS (acquired).
Rohlen, who leads a holdings company backed by private equity giant KKR, previously served as chairman and CEO of EPIX, Co-founder, Chairman and CEO of Spirox, Inc (sold to Entellus Medical) and co-founder and CEO of CV Ingenuity. He was also president of Fox Hollow before it was acquired by EV3.
In this podcast we’ll learn how VCs are looking at investment opportunities in this market
- Are they making new investments?
- What impact is this having on valuation?
- Do VCs give stronger consideration to new concerns like supply chain?
- How are they managing burn rates in their existing portfolio companies?
- When will they get clinical trials up and running?
Don’t miss an episode! Subscribe to DeviceTalks Weekly on your podcast players.